APA

Amorosa V. K., Luetkemeyer A., Kang M., Johnson V. A., Umbleja T., Haas D. W., Yesmin S., Bardin M. C., Chung R. T., Alston-Smith B., Tebas P. & Peters M. G. (20140130). Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. : HIV clinical trials.

Chicago

Amorosa Valerianna K, Luetkemeyer Anne, Kang Minhee, Johnson Victoria A, Umbleja Triin, Haas David W, Yesmin Suria, Bardin Matthew C, Chung Ray T, Alston-Smith Beverly, Tebas Pablo and Peters Marion G. 20140130. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. : HIV clinical trials.

Harvard

Amorosa V. K., Luetkemeyer A., Kang M., Johnson V. A., Umbleja T., Haas D. W., Yesmin S., Bardin M. C., Chung R. T., Alston-Smith B., Tebas P. and Peters M. G. (20140130). Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. : HIV clinical trials.

MLA

Amorosa Valerianna K, Luetkemeyer Anne, Kang Minhee, Johnson Victoria A, Umbleja Triin, Haas David W, Yesmin Suria, Bardin Matthew C, Chung Ray T, Alston-Smith Beverly, Tebas Pablo and Peters Marion G. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. : HIV clinical trials. 20140130.